Study of Tinidazole to Treat Mycoplasma Genitalium in Men with Non-gonococcal Urethritis at the Seattle & King County Sexual Health Clinic

What this Trial Is About

Researchers are evaluating the effectiveness of tinidazole for treating Mycoplasma genitalium MG infection in male patients diagnosed with non-gonococcal urethritis NGU. This study focuses on men who have tested positive for MG and have received standard doxycycline therapy. Tinidazole is a drug approved for other infections but has not been systematically tested against MG, and this trial aims to assess its potential in treating this condition. Participants will receive tinidazole starting with a 2-gram dose orally on the first day, followed by 500 mg taken twice daily for the next nine days. This is a single-arm study conducted at a sexual health clinic where men with NGU will be enrolled. Treatment effectiveness will be evaluated through microbiologic tests 21 days after completing the tinidazole regimen. During the study, urine specimens will be collected at diagnosis, at the start of tinidazole therapy, and at the test of cure visit. These samples will be used to assess bacterial load, culture, and resistance to tinidazole. The main outcome is microbiologic cure of MG by day 38. Participants will be monitored for antimicrobial susceptibility and resistance mutations to better understand treatment response. The study will be conducted until August 2026.

"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"